Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

HAEMATOLOGICAL CANCER

ALCYONE — lighting the way for quadruplet therapy of NDMM

Nature Reviews Clinical Oncology volume 17, page 67 (2020)Cite this article

Subjects

Access through your institution
Buy or subscribe

Combination therapies incorporating immunomodulatory drugs and/or proteasome inhibitors have become the standard of care for patients with newly diagnosed multiple myeloma (NDMM), including the bortezomib, melphalan and prednisone (VMP) triplet for transplant-ineligible patients. New findings support the addition of the anti-CD38 antibody daratumumab to this regimen.

Importantly, these improvements translated into an overall survival (OS) benefit: 3-year OS was 78.0% with D-VMP versus 67.9% with VMP alone (HR 0.60, 95% CI 0.46–0.80; P = 0.0003). The OS hazard ratios were broadly similar across all pre-specified subgroups of patients, except those with high-risk cytogenetic features, who seemed to only modestly benefit from D-VMP (HR 0.91, 95% CI 0.50–1.65); however, this subgroup was small, comprising only 14% of patients, and greater benefit might emerge with longer follow-up study “D-VMP is the first daratumumab-based regimen with a demonstrated OS benefit in the first-line setting and is a new standard of care for transplant-ineligible patients with NDMM,” states Mateos. This treatment approach was approved by the FDA in May 2018.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    David Killock

Authors
  1. David Killock
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to David Killock.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Killock, D. ALCYONE — lighting the way for quadruplet therapy of NDMM. Nat Rev Clin Oncol 17, 67 (2020). https://doi.org/10.1038/s41571-019-0321-2

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41571-019-0321-2

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing